Comparative Analysis Between the HER2 Status in Primary Breast Cancer Tissue and the Detection of Isolated Tumor Cells in the Bone Marrow

[1]  S. Kakar,et al.  HER-2/neu Assessment in Breast Cancer by Immunohistochemistry and Fluorescence In Situ Hybridization: Comparison of Results and Correlation With Survival , 2000, Molecular Diagnosis.

[2]  D. Larsimont,et al.  Evaluation of HER-2/NEU Protein Expression in Breast Cancer by Immunohistochemistry: An Interlaboratory Study Assessing the Reproducibility of HER-2/NEU Testing , 2002, Breast Cancer Research and Treatment.

[3]  J. Kovarik,et al.  Prognostic value of bone marrow biopsy in operable breast cancer patients at the time of initial diagnosis: Results of a 20-year median follow-up , 1998, Breast Cancer Research and Treatment.

[4]  G Kvalheim,et al.  Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Bartlett,et al.  The clinical evaluation of HER‐2 status: which test to use? , 2003, The Journal of pathology.

[6]  M. Dowsett,et al.  Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER‐2 in 426 breast carcinomas from 37 centres , 2003, The Journal of pathology.

[7]  N. Hynes,et al.  The ErbB receptors and their role in cancer progression. , 2003, Experimental cell research.

[8]  R. Kåresen,et al.  Assessment of HER‐2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be the method of choice? , 2003, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[9]  M. Dowsett,et al.  Current Status of HER2 Testing , 2002, Oncology.

[10]  Jong-Hyeon Jeong,et al.  Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. , 2002, The New England journal of medicine.

[11]  Peter A Kaufman,et al.  Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. , 2002, Journal of the National Cancer Institute.

[12]  I. Smith,et al.  The development and clinical use of trastuzumab (Herceptin). , 2002, Endocrine-related cancer.

[13]  G. Mikuz,et al.  Prognostic significance of Ep‐CAM AND Her‐2/neu overexpression in invasive breast cancer , 2002, International journal of cancer.

[14]  S. Tsutsui,et al.  Prognostic value of c‐erbB2 expression in breast cancer , 2002, Journal of Surgical Oncology.

[15]  Lyndsay N Harris,et al.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  S. Singletary,et al.  Prognostic Factors in Node-Negative Breast Cancer: A Review of Studies With Sample Size More Than 200 and Follow-Up More Than 5 Years , 2002, Annals of surgery.

[17]  G Kvalheim,et al.  Detection of isolated tumor cells in bone marrow in early-stage breast carcinoma patients: comparison with preoperative clinical parameters and primary tumor characteristics. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  J. R. Reeves,et al.  Evaluating HER2 amplification and overexpression in breast cancer , 2001, The Journal of pathology.

[19]  S. Braun,et al.  Molecular determinants of occult metastatic tumor cells in bone marrow. , 2001, Clinical breast cancer.

[20]  N. Semprasert,et al.  Immunohistochemical study of c-erbB-2 expression in primary breast cancer. , 2001, Asian Pacific journal of allergy and immunology.

[21]  T. Fehm,et al.  Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: clinical outcome during long-term follow-up. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Mathieu,et al.  c‐erbB‐2 (HER‐2/neu) gene amplification is a better indicator of poor prognosis than protein over‐expression in operable breast‐cancer patients , 2001, International journal of cancer.

[23]  S. Braun,et al.  The fate and prognostic value of occult metastatic cells in the bone marrow of patients with breast carcinoma between primary treatment and recurrence , 2001, Cancer.

[24]  W. Hanna.  Testing for HER2 Status , 2001, Oncology.

[25]  S. Braun,et al.  ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. , 2001, Cancer research.

[26]  T. Reimer,et al.  Simultaneous immunohistochemical detection of tumor cells in lymph nodes and bone marrow aspirates in breast cancer and its correlation with other prognostic factors. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  A. Yayon,et al.  Soluble and matrix‐associated heparan sulfate proteoglycans increase expression of erb‐B2 and erb‐B3 in colon cancer cell lines , 2001, International journal of cancer.

[28]  M. Untch,et al.  Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  A Lanigan,et al.  HER2 as a prognostic and predictive marker for breast cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  D. Slamon,et al.  Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Mike Clarke,et al.  UK and USA breast cancer deaths down 25% in year 2000 at ages 20–69 years , 2000, The Lancet.

[32]  T. Dimpfl,et al.  Prognostic significance of an increased number of micrometastatic tumor cells in the bone marrow of patients with first recurrence of breast carcinoma , 2000, Cancer.

[33]  T. Dimpfl,et al.  Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. , 2000, The New England journal of medicine.

[34]  H Sommer,et al.  Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  S. Braun,et al.  Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  R. Coombes,et al.  Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study , 1999, The Lancet.

[37]  J. Ross,et al.  The HER‐2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy , 1998, Stem cells.

[38]  S. Fox,et al.  Association of tumor angiogenesis with bone marrow micrometastases in breast cancer patients. , 1997, Journal of the National Cancer Institute.

[39]  G. Schlimok,et al.  Detection of genetic alterations in micrometastatic cells in bone marrow of cancer patients by fluorescence in situ hybridization. , 1996, Cancer genetics and cytogenetics.

[40]  A. Luini,et al.  Immunodetection of bone marrow micrometastases in breast carcinoma patients and its correlation with primary tumour prognostic features. , 1994, British Journal of Cancer.

[41]  D. Slamon,et al.  Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. , 1994, Cancer research.

[42]  J. Izbicki,et al.  Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. , 1993, Journal of the National Cancer Institute.

[43]  J. Sloane,et al.  Potential pathological application of immunocytochemical methods to the detection of micrometastases. , 1980, Cancer research.